Evidence map›Paper›PMID 34001096›Full record

Trial reportBMC medicine2021

Evaluation of a serum-based antigen test for tuberculosis in HIV-exposed infants: a diagnostic accuracy study.

Liyan Mao, Sylvia M LaCourse, Soyeon Kim, Chang Liu, Bo Ning, Duran Bao, Jia Fan, Christopher J Lyon, Ziyong Sun, Sharon Nachman and 2 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023
    Review
  8. Review and Updates on the Diagnosis of Tuberculosis.Journal of clinical medicine · 2022
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Liyan MaoCenter for Cellular and Molecular Diagnostics, Biochemistry and Molecular Biology, Tulane University School of Medicine, Room 474, 333 S. Liberty Street, New Orleans, LA, 70112, USA.
Sylvia M LaCourseDepartments of Medicine and Global Health, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98104, USA.
Soyeon KimFrontier Science Foundation, Brookline, MA, 02115, USA.
Chang LiuDepartment of Chemical Engineering, Biomedical Engineering Program, University of South Carolina, Columbia, SC, 29208, USA.
Bo NingCenter for Cellular and Molecular Diagnostics, Biochemistry and Molecular Biology, Tulane University School of Medicine, Room 474, 333 S. Liberty Street, New Orleans, LA, 70112, USA.
Duran BaoCenter for Cellular and Molecular Diagnostics, Biochemistry and Molecular Biology, Tulane University School of Medicine, Room 474, 333 S. Liberty Street, New Orleans, LA, 70112, USA.
Jia FanCenter for Cellular and Molecular Diagnostics, Biochemistry and Molecular Biology, Tulane University School of Medicine, Room 474, 333 S. Liberty Street, New Orleans, LA, 70112, USA.
Christopher J LyonCenter for Cellular and Molecular Diagnostics, Biochemistry and Molecular Biology, Tulane University School of Medicine, Room 474, 333 S. Liberty Street, New Orleans, LA, 70112, USA.
Ziyong SunDepartment of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Sharon NachmanDepartment of Pediatrics, State University of New York at Stony Brook, Stony Brook, NY, 11794, USA.
Charles D Mitchell *Department of Pediatrics, Division of Infectious Diseases and Immunology, University of Miami Miller School of Medicine, Batchelor Children's Research Institute, Room 286, 1580 NW 10th Avenue, Miami, FL, 33136, USA. cmitchel@med.miami.edu.
Tony Y Hu *Center for Cellular and Molecular Diagnostics, Biochemistry and Molecular Biology, Tulane University School of Medicine, Room 474, 333 S. Liberty Street, New Orleans, LA, 70112, USA. tonyhu@tulane.edu.
Tulane University · USHuazhong University of Science and Technology · CNFrontier Science & Technology Research Foundation · USState University of New York · USUniversity of Miami · USUniversity of South Carolina · USUniversity of Washington · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Direct quantitation of the circulating Mtb-peptidome for pediatric TB managementR01HD090927 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI Christopher J Lyon, Charles DeBeaux Mitchell · 2017 to 2026
$4.5M
Quantification of Circulating Antigens for Pediatric TB Diagnosis andTreatment MonitoringR01AI122932 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HU, TONY Y. · 2016 to 2019
$1.8M
Real-time Detection of Active TB in HIV Exposed Children on CustomizedNanotrapR01AI113725 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LABAER, JOSHUA · 2015 to 2018
$1.6M
Impact of maternal HIV on Mycobacterium tuberculosis infection among peripartum women and their infantsK23AI120793 · NIAID · UNIVERSITY OF WASHINGTON · PI LACOURSE, SYLVIA · 2016 to 2020
$910k
NanoDisk-MS measured Mtb antigen peptides for TB diagnosis and treatment monitoring in HIV-infected childrenR21AI143341 · NIAID · UNIVERSITY OF WASHINGTON · PI LACOURSE, SYLVIA · 2019 to 2020
$443k
Multiplexed quantification of circulating peptidomic signatures for EBOLA early diagnosisR21AI126361 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI LABAER, JOSHUA · 2017 to 2018
$373k
NIAID NIH HHS K23 AI120793NIAID NIH HHS R01 AI113725NIAID NIH HHS R01 AI122932NIAID NIH HHS R21 AI126361NIAID NIH HHS R21 AI143341NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI106716NICHD NIH HHS HHSN275201800001CNICHD NIH HHS HHSN275201800001INICHD NIH HHS R01 HD090927
6 · The paper itself

Abstract

backgroundNon-sputum methods are urgently needed to improve tuberculosis diagnosis and treatment monitoring in children. This study evaluated the ability of a serum assay quantifying a species-specific peptide of the Mycobacterium tuberculosis CFP-10 virulence factor via nanotechnology and matrix-assisted laser desorption ionization time-of-flight mass spectrometry to diagnose tuberculosis in HIV-infected and HIV-uninfected infants.

methodsSerum CFP-10 peptide signal was blinded evaluated in cryopreserved sera of 519 BCG-immunized, HIV-exposed infants (284 HIV-infected, 235 HIV-uninfected) from a multi-center randomized placebo-controlled isoniazid prophylaxis trial conducted in southern Africa between 2004 and 2008, who were followed up to 192 weeks for Mtb infection and TB. Children were classified as confirmed, unconfirmed, or unlikely tuberculosis cases using 2015 NIH diagnostic criteria for pediatric TB.

resultsIn HIV-infected infants, CFP-10 signal had 100% sensitivity for confirmed TB (5/5, 95% CI, 47.8-100) and 83.7% sensitivity for unconfirmed TB (36/43, 95% CI 69.3-93.2), with 93.1% specificity (203/218, 95% CI 88.9-96.1). In HIV-uninfected infants, CFP-10 signal detected the single confirmed TB case and 75.0% of unconfirmed TB cases (15/20; 95% CI 50.9-91.3), with 96.2% specificity (177/184, 95% CI, 92.3-98.5). Serum CFP-10 achieved 77% diagnostic sensitivity for confirmed and unconfirmed TB (13/17, 95% CI, 50-93%) at ≤ 24 weeks pre-diagnosis, and both CFP-10-positivity and concentration declined following anti-TB therapy initiation.

conclusionsSerum CFP-10 signal exhibited high diagnostic sensitivity and specificity for tuberculosis in HIV-infected and HIV-uninfected infants and potential utility for early TB detection and monitoring of anti-TB treatment responses.

Indexed as

HIV InfectionsMycobacterium tuberculosisTuberculosisAntigens, BacterialChildHumansInfantIsoniazidSensitivity and SpecificityAntigens, BacterialIsoniazidCFP-10Mass spectrometryNanotechnologyPediatric tuberculosis

Identifiers

PMID34001096
PMCPMC8130139
OpenAlexW3163800872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.